Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter June 1, 2005

Serum Amyloid A Protein (SAA) in Colorectal Carcinoma

  • Ines Glojnarić , Martin-Tino Časl , Diana Šimić and Josip Lukač

Abstract

The changes in serum levels of serum amyloid A protein were studied in 67 patients suffering from colorectal carcinoma and compared to three other major acute phase proteins: C-reactive protein, α1-antichymotrypsin and α1-acid glycoprotein. Although the presence of colorectal carcinoma caused an increase in serum levels of all the acute phase reactants studied, serum amyloid A protein showed the most powerful reaction in pre-operative disease stage, with the mean value of 330 mg/l (range 7–2506 mg/l) as compared to the normal values of <1.2 mg/l obtained in 30 healthy adults. The mean serum amyloid A protein concentration increased to 487 mg/l after surgery, declining during the post-operative clinical course until the sixth chemotherapy cycle (from 167mg/l to 64 mg/l), but never returned to the normal range. In the later chemotherapy cycles, mean serum amyloid A protein increased to 163 mg/l, probably as a result of the disease relapse. According to the statistical relations among exact confidence intervals for proportions, serum amyloid A protein showed the best specificity for colorectal carcinoma of all the acute phase proteins studied (83–100%) and also a sensitivity of 100%. We concluded that serum amyloid A protein seems to be a reliable parameter, which could be recommended for clinical routine as a non-specific tumour marker for colorectal carcinoma.

:
Published Online: 2005-06-01
Published in Print: 2001-04-09

Copyright © 2001 by Walter de Gruyter GmbH & Co. KG

Downloaded on 2.5.2024 from https://www.degruyter.com/document/doi/10.1515/CCLM.2001.022/html
Scroll to top button